HTL-Strefa S.A.
8
0
0
8
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 8 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 8 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (8)
Simulated Clinical Use Testing to Evaluate Sharps Injury Prevention Features of HTL-STREFA's Safety Lancets (Test C)
Role: lead
The Characteristics of Different Personal Lancets on Blood Volume and Perceived Pain in Patients With Diabetes Mellitus
Role: lead
Comparison of Three Lancing Devices Regarding Capillary Blood Volume and Lancing Pain Intensity.
Role: lead
Characteristics of Different Types of Safety Lancets on Blood Volume and Perceived Pain in Male and Female Volunteers
Role: lead
Simulated Clinical Use Testing On Safety Lancets (Test B)
Role: lead
Simulated Clinical Use Testing on Safety Lancets (Test A)
Role: lead
Simulated Clinical Use Testing on the DropSafe Safety Pen Needle
Role: lead
Capillary Blood Volume and Pain Perception Obtained in a Process of Puncturing With Different Safety Lancets
Role: lead
All 8 trials loaded